Wnt & β-Catenin Targeted Drug Discovery Summit – The Only Conference that will Accelerate Your Discovery & Development of Wnt/β-catenin-Targeted Drugs

Over the last 2 decades, scientists and drug developers have been puzzled yet fascinated by Wnt/β-Catenin – its role in maintaining cancer stem cells, regulating numerous gene expressions that control development and tissue homeostasis, and potential to eliminate cancer relapse is too appealing to give up on. Albeit challenging and multiple setbacks, 2021 might be the hallmark year where drug developers and leading academics celebrate an essential milestone of Wnt/β-Catenin inhibition.

The Wnt & β-Catenin Targeted Drug Discovery Summit is devoted to examining the underlying preclinical model strategies that can accelerate your novel Wnt/β-catenin candidates into the clinic and market.

Download your copy of the agenda now 

This year’s program has been designed to allow you to unpick learnings from pioneering biopharma companies breaking down and addressing each of these key factors in detail:

• New Ways to Attack an Armadillo – Latest Approaches to Inhibit β-Catenin Signaling – Explore different modalities including Creb, siRNA, PROTAC, and bispecific – what is the best route to tame Wnt and β-catenin? – key insights from The Ohio State University, Iterion Therapeutics & Saint John’s Cancer Institute 
• Harnessing Organoids for Pre-Clinical Research – Narrating the behavior and mechanistic actions of organoids and cell culture detailing the preclinical applications of organoids – Marc Van Wetering Senior Researcher, Clevers Group Prinses Máxima Centrum 
• ​Targeting DKK1 in Cancer – Delving into the development of a DKK1 RNAscope biomarker assay and sharing results from their clinical trial – Mike Kagey Senior Director of Translational Medicine Leap Therapeutics 
• Turning the Undruggable Druggable into the Next Blockbuster: β-Catenin – Understanding approaches towards drugging β-catenin and other intractable targets, especially transcription factors – Greg Verdine Chairman, President & CEO Fog Pharma
• Any many more sessions!

Across 2 days, you will be joined by 80+ senior scientists from drug developers, including the likes of FogPharma, Genentech, Iterion Therapeutics, demonstrating the scientific proof of concept, MoA and commercial potential of Wnt/β-Catenin – which will potentially outweigh RAS as your next blockbuster drug target in the next 5 years.

Join us on November 17 & 18 and book your place today here to save up to $550.